美国 · SEC FORM 4
Tourmaline Bio, Inc.
TRML · — · CIK 0001827506 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-08-21 · Kulkarni Sandeep Chidambar.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-08-21 | Kulkarni Sandeep Chidambar | 买入 (P) | Common Stock | 1,779 | USD 14.85 | USD 26,418 | SEC 申报 ↗ |
| 2024-08-16 | Kulkarni Sandeep Chidambar | 买入 (P) | Common Stock | 5,221 | USD 13.79 | USD 71,998 | SEC 申报 ↗ |
| 2024-01-29 | MCDADE MARK | 买入 (P) | Common Stock | 100,000 | USD 32.50 | USD 3,250,000 | SEC 申报 ↗ |
| 2023-11-17 | Thiara Parvinder | 买入 (P) | Common Stock | 1,000 | USD 17.31 | USD 17,310 | SEC 申报 ↗ |
| 2023-11-17 | Kulkarni Sandeep Chidambar | 买入 (P) | Common Stock | 4,000 | USD 16.99 | USD 67,960 | SEC 申报 ↗ |
| 2023-10-27 | Castelein Caley | 买入 (P) | Common Stock | 15,800 | USD 14.55 | USD 229,890 | SEC 申报 ↗ |
| 2023-10-26 | Kulkarni Sandeep Chidambar | 买入 (P) | Common Stock | 5,000 | USD 12.25 | USD 61,250 | SEC 申报 ↗ |
| 2023-10-25 | Castelein Caley | 买入 (P) | Common Stock | 4,200 | USD 12.07 | USD 50,694 | SEC 申报 ↗ |
| 2023-10-25 | Thiara Parvinder | 买入 (P) | Common Stock | 2,000 | USD 12.12 | USD 24,240 | SEC 申报 ↗ |
| 2023-10-24 | Thiara Parvinder | 买入 (P) | Common Stock | 5,000 | USD 10.66 | USD 53,300 | SEC 申报 ↗ |
| 2023-10-24 | Kulkarni Sandeep Chidambar | 买入 (P) | Common Stock | 4,650 | USD 10.68 | USD 49,662 | SEC 申报 ↗ |
| 2023-10-24 | KANTOFF AARON | 买入 (P) | Common Stock | 7,500 | USD 11.86 | USD 88,950 | SEC 申报 ↗ |
| 2022-07-29 | Requadt Scott | 买入 (P) | Common Stock | 39,382 | USD 4.25 | USD 167,374 | SEC 申报 ↗ |
| 2022-07-28 | Requadt Scott | 买入 (P) | Common Stock | 3,090 | USD 4.25 | USD 13,132 | SEC 申报 ↗ |
| 2022-07-26 | Requadt Scott | 买入 (P) | Common Stock | 5,528 | USD 4.24 | USD 23,439 | SEC 申报 ↗ |
Form 4 申报证据
22 transaction lines in the latest 365-day window; 148 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-28 | Thiara Parvinder | U (U) | Common Stock | 83,782 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Srivastava Sapna | U (U) | Common Stock | 518 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Robinson Ryan F. | U (U) | Common Stock | 14,366 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (17 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-28 | Thiara Parvinder | U (U) | Common Stock | 83,782 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Srivastava Sapna | U (U) | Common Stock | 518 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Robinson Ryan F. | U (U) | Common Stock | 14,366 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | MIDDLEKAUFF W BRADFORD | U (U) | Common Stock | 60,988 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | MIDDLEKAUFF W BRADFORD | D (D) | Common Stock | 8,213 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | MCDADE MARK | U (U) | Common Stock | 742,209 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Kulkarni Sandeep Chidambar | U (U) | Common Stock | 731,664 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Kulkarni Sandeep Chidambar | D (D) | Common Stock | 30,387 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | KANTOFF AARON | U (U) | Common Stock | 88,281 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Jones Susan Dana | U (U) | Common Stock | 19,782 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Jones Susan Dana | D (D) | Common Stock | 3,152 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Johnson Kevin Bruce | U (U) | Common Stock | 40,538 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Johnson Kevin Bruce | D (D) | Common Stock | 11,046 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-28 | Castelein Caley | U (U) | Common Stock | 947,936 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-24 | KANTOFF AARON | 赠与 (G) | Common Stock | 5,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-10-22 | Robinson Ryan F. | 期权行权/转换 (M) | Common Stock | 14,366 | USD 13.92 | USD 199,975 | SEC 申报 ↗ |
| 2025-10-22 | Kulkarni Sandeep Chidambar | 期权行权/转换 (M) | Common Stock | 25,316 | USD 7.90 | USD 199,996 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TRML |
| CIK | 0001827506 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 148 transaction lines from 2021-05-11 to 2025-10-28 38 P purchase lines · 28 S sale lines · 82 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.